In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Selected Start-Ups (11/00)

Executive Summary

In Vivo summarizes the technologies of several recently founded companies: CryoCor Inc.will use cryonic ablation technology to treat cardiac arrhythmias. Expert Biomed Inc.is engaged in the search for therapeutics for Alzheimer's disease as well as new cancer diagnostics. Hypnion Inc. will use specialized screening and functional genomics services to discover novel drugs for sleep disorders and circadian rhythm abnormalities. France's Nautilus Biotech will use its proprietary analytical and gene transfer vector technology to support the drug discovery efforts of its customers. Neurogenetics Inc. aims to develop small molecule therapeutics to halt the progression of Alzheimer's disease and other neurodegenerative disorders. Robinson Medical Inc. will commercialize technology for the non-invasive continuous, real-time measurement of blood flow during cardiac surgery.

You may also be interested in...



Genus Triumphs Over FDA In Barium Sulfate Product Classification Suit

The decision limits US FDA discretion in determining how to regulate products that seem to meet both drug and device standards.

Deal Watch: Gain To Test Enzyme-Enhancement Tech In Cancer With Zentalis

Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.

Tech Transfer Roundup: BridgeBio’s R&D Efforts Span New Seven New Agreements

Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.

Related Companies

UsernamePublicRestriction

Register

IV001328

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel